These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 24854991

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA.
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, Liu W, Dong S, Redell M, Mo Q, Song Y.
    J Hematol Oncol; 2016 Mar 12; 9():24. PubMed ID: 26970896
    [Abstract] [Full Text] [Related]

  • 6. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW, Armstrong SA.
    Exp Hematol; 2015 Aug 12; 43(8):673-84. PubMed ID: 26118503
    [Abstract] [Full Text] [Related]

  • 7. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
    Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL.
    Blood; 2011 May 05; 117(18):4759-68. PubMed ID: 21398221
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of DOT1L in the maintenance of leukemia gene expression.
    Wang X, Chen CW, Armstrong SA.
    Curr Opin Genet Dev; 2016 Feb 05; 36():68-72. PubMed ID: 27151433
    [Abstract] [Full Text] [Related]

  • 13. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y, Ge S.
    J Hematol Oncol; 2022 Mar 24; 15(1):35. PubMed ID: 35331314
    [Abstract] [Full Text] [Related]

  • 14. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H, van Leeuwen F.
    Chromosoma; 2016 Sep 24; 125(4):593-605. PubMed ID: 26728620
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
    Wang E, Kawaoka S, Yu M, Shi J, Ni T, Yang W, Zhu J, Roeder RG, Vakoc CR.
    Proc Natl Acad Sci U S A; 2013 Mar 05; 110(10):3901-6. PubMed ID: 23412334
    [Abstract] [Full Text] [Related]

  • 20. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
    Okuda H, Stanojevic B, Kanai A, Kawamura T, Takahashi S, Matsui H, Takaori-Kondo A, Yokoyama A.
    J Clin Invest; 2017 May 01; 127(5):1918-1931. PubMed ID: 28394257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.